Advertisement

Drugmakers pledge restraint, but prices will still soar

By Associated Press  |  February 27, 2017

Several big drugmakers are trying to quell the ongoing furor over high drug prices by revealing more information about their pricing and even pledging to keep a lid on increases.

Best Practices: Improve device reprocessing through collaborative learning

Best Practices: Improve device reprocessing through collaborative learning

By Adam Rubenfire  |  June 04, 2016

Five years ago, medical-device maker Ethicon acquired Sterilmed, a company that reprocesses and remanufactures medical devices. The combination helped Ethicon executives recognize the cost-efficiency and environmental benefits that could come from better reprocessing services and more collaboration...

Editorial: What's a new cancer drug worth?

Editorial: What's a new cancer drug worth?

By Merrill Goozner  |  May 21, 2016

While the latest cancer drugs emerging from drug and biotechnology company labs can come with hefty price tags, they don't necessarily have a lot of evidence showing they actually work.

Special deals, circumstances propel healthcare CEO pay

Special deals, circumstances propel healthcare CEO pay

By Dave Barkholz  |  April 16, 2016

Joe Kiani, founder of Masimo Corp., has vaulted to the top of the list of healthcare's highest paid executives through an unusual golden parachute built into his stock option plan. Special deals and special circumstances dominated this year's list of top-paid CEOs in Modern Healthcare's analysis.

FDA approves biosimilar of J&J's money maker Remicade

By Associated Press  |  April 05, 2016

The approval of Inflectra Tuesday is only the second time that the FDA has approved a quasi-generic version of a biotech drug for the U.S. market. Remicade, a medicine for inflammatory diseases, had $6.56 billion in sales last year.

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print